Literature DB >> 23086186

Benefit and harm from immunity to respiratory syncytial virus: implications for treatment.

Maximillian S Habibi1, Peter J M Openshaw.   

Abstract

PURPOSE OF REVIEW: Human respiratory syncytial virus (RSV) infection is a major cause of morbidity in children and of morbidity and mortality in elderly or immunocompromised adults. Given prophylactically, antibody can protect against infection, but natural levels are poorly protective. Vaccination may enhance disease, and there is no well tolerated and effective vaccine or antiviral treatment. Despite over 50 years of research, therapy remains nonspecific and supportive. RECENT
FINDINGS: Experimental human challenge in adult volunteers is beginning to elucidate the dynamics of viral shedding and causes of disease, but investigations of naturally infected children remain logistically challenging. RSV was known to bind several surface ligands, but the recent demonstration that nucleolin acts as a receptor for the RSV fusion protein was unexpected. Recent studies increasingly emphasize the relevance of innate immune responses and the dysregulation of inflammation as key factors in causing the pathological effects of infection. Studies in both human infants and mice indicate that interleukin-17 plays a role in some forms of RSV disease and regulatory T cells may be important in controlling inflammation.
SUMMARY: Improved understanding of the human immune response to RSV infection continues to be needed in order to accelerate the development of vaccines and new treatments for bronchiolitis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23086186     DOI: 10.1097/QCO.0b013e32835a1d92

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  12 in total

1.  Editorial: RSV, dendritic cells, and allergens--a bad combination.

Authors:  Stefan Worgall
Journal:  J Leukoc Biol       Date:  2013-07       Impact factor: 4.962

2.  Axl receptor blockade ameliorates pulmonary pathology resulting from primary viral infection and viral exacerbation of asthma.

Authors:  Takehiko Shibata; David M Habiel; Ana L Coelho; Steven L Kunkel; Nicholas W Lukacs; Cory M Hogaboam
Journal:  J Immunol       Date:  2014-03-21       Impact factor: 5.422

3.  IL-17E (IL-25) and IL-17RB promote respiratory syncytial virus-induced pulmonary disease.

Authors:  Bryan C Petersen; Vladislav Dolgachev; Andrew Rasky; Nicholas W Lukacs
Journal:  J Leukoc Biol       Date:  2014-01-09       Impact factor: 4.962

4.  Maternal immunization with chimpanzee adenovirus expressing RSV fusion protein protects against neonatal RSV pulmonary infection.

Authors:  Anurag Sharma; Rebecca Wendland; Biin Sung; Wenzhu Wu; Thomas Grunwald; Stefan Worgall
Journal:  Vaccine       Date:  2014-08-26       Impact factor: 3.641

Review 5.  The role of Th17 and Treg responses in the pathogenesis of RSV infection.

Authors:  Thomas C Mangodt; Mikhaïl A Van Herck; Sara Nullens; José Ramet; Jozef J De Dooy; Philippe G Jorens; Benedicte Y De Winter
Journal:  Pediatr Res       Date:  2015-08-12       Impact factor: 3.756

6.  Respiratory syncytial virus persistence in macrophages upregulates Fcgamma receptors expression.

Authors:  Jorge Gaona; Carlos Santiago-Olivares; Enrique Ortega; Beatriz Gómez
Journal:  Viruses       Date:  2014-02-06       Impact factor: 5.048

Review 7.  Modulation of Respiratory TLR3-Anti-Viral Response by Probiotic Microorganisms: Lessons Learned from Lactobacillus rhamnosus CRL1505.

Authors:  Haruki Kitazawa; Julio Villena
Journal:  Front Immunol       Date:  2014-05-12       Impact factor: 7.561

8.  Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism.

Authors:  Corinna Schnoeller; Xavier Roux; Devika Sawant; Dominique Raze; Wieslawa Olszewska; Camille Locht; Peter J Openshaw
Journal:  Am J Respir Crit Care Med       Date:  2014-01-15       Impact factor: 30.528

Review 9.  Th17 lymphocytes in respiratory syncytial virus infection.

Authors:  Jonas Bystrom; Nasra Al-Adhoubi; Mohammed Al-Bogami; Ali S Jawad; Rizgar A Mageed
Journal:  Viruses       Date:  2013-03-05       Impact factor: 5.048

10.  Regulatory T cells prevent Th2 immune responses and pulmonary eosinophilia during respiratory syncytial virus infection in mice.

Authors:  Lydia R Durant; Spyridon Makris; Cornelia Maaike Voorburg; Jens Loebbermann; Cecilia Johansson; Peter J M Openshaw
Journal:  J Virol       Date:  2013-08-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.